Repros’ Androxal Primed For NDA Submission, But Outcomes Study Looms
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The testosterone drugmaker is confident that Androxal can gain approval and is on track to submit a filing with FDA this year, but a cardiovascular outcomes study is still on the table.
You may also be interested in...
Repros Low-Testosterone Therapy NDA May Be Delayed Until 4Q 2014
The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.